Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gordon J Freeman

Showing results (291-300 of 348) with videos related to

Pageof 35
Sort By:
Cell Reports|December 2, 2014
CD161 defines a transcriptional and functional phenotype across distinct human T cell lineagesJoannah R Fergusson, Kira E Smith, Vicki M Fleming, et al.
Cell Research|November 12, 2025
Targeted destruction of VISTA boosts anti-tumor immunotherapyLi Chen, Xia Bu, Yishuang Sun, et al.
Cancer Immunology Research|October 18, 2017
Tumor PDCD1LG2 (PD-L2) Expression and the Lymphocytic Reaction to Colorectal CancerYohei Masugi, Reiko Nishihara, Tsuyoshi Hamada, et al.
Nature Communications|September 27, 2019
Metabolomic adaptations and correlates of survival to immune checkpoint blockadeHaoxin Li, Kevin Bullock, Carino Gurjao, et al.
Science Immunology|January 16, 2021
PD-1 blockade exacerbates <i>Mycobacterium tuberculosis</i> infection in rhesus macaquesKeith D Kauffman, Shunsuke Sakai, Nickiana E Lora, et al.
JCI Insight|October 5, 2016
Synergy of radiotherapy and PD-1 blockade in Kras-mutant lung cancerGrit S Herter-Sprie, Shohei Koyama, Houari Korideck, et al.
Cell Chemical Biology|September 26, 2023
Targeting METTL3 reprograms the tumor microenvironment to improve cancer immunotherapyHaisheng Yu, Jing Liu, Xia Bu, et al.
Genome Biology|October 16, 2020
Clonal tracing reveals diverse patterns of response to immune checkpoint blockadeShengqing Stan Gu, Xiaoqing Wang, Xihao Hu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 24, 2019
irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical TrialJean-Christophe Pignon, Opeyemi Jegede, Sachet A Shukla, et al.
Immunity|September 14, 2022
Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12Christopher S Garris, Sean P Arlauckas, Rainer H Kohler, et al.
Pageof 35

Showing results (291-300 of 348) with videos related to

Sort By:
Pageof 35
Cell Reports|December 2, 2014
CD161 defines a transcriptional and functional phenotype across distinct human T cell lineagesJoannah R Fergusson, Kira E Smith, Vicki M Fleming, et al.
Cell Research|November 12, 2025
Targeted destruction of VISTA boosts anti-tumor immunotherapyLi Chen, Xia Bu, Yishuang Sun, et al.
Cancer Immunology Research|October 18, 2017
Tumor PDCD1LG2 (PD-L2) Expression and the Lymphocytic Reaction to Colorectal CancerYohei Masugi, Reiko Nishihara, Tsuyoshi Hamada, et al.
Nature Communications|September 27, 2019
Metabolomic adaptations and correlates of survival to immune checkpoint blockadeHaoxin Li, Kevin Bullock, Carino Gurjao, et al.
Science Immunology|January 16, 2021
PD-1 blockade exacerbates <i>Mycobacterium tuberculosis</i> infection in rhesus macaquesKeith D Kauffman, Shunsuke Sakai, Nickiana E Lora, et al.
JCI Insight|October 5, 2016
Synergy of radiotherapy and PD-1 blockade in Kras-mutant lung cancerGrit S Herter-Sprie, Shohei Koyama, Houari Korideck, et al.
Cell Chemical Biology|September 26, 2023
Targeting METTL3 reprograms the tumor microenvironment to improve cancer immunotherapyHaisheng Yu, Jing Liu, Xia Bu, et al.
Genome Biology|October 16, 2020
Clonal tracing reveals diverse patterns of response to immune checkpoint blockadeShengqing Stan Gu, Xiaoqing Wang, Xihao Hu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 24, 2019
irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical TrialJean-Christophe Pignon, Opeyemi Jegede, Sachet A Shukla, et al.
Immunity|September 14, 2022
Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12Christopher S Garris, Sean P Arlauckas, Rainer H Kohler, et al.
Pageof 35